Venturi Wealth Management LLC Makes New $86,000 Investment in Insmed Incorporated (NASDAQ:INSM)

Venturi Wealth Management LLC acquired a new stake in shares of Insmed Incorporated (NASDAQ:INSM) during the fourth quarter, Holdings Channel reports. The fund acquired 1,250 shares of the biopharmaceutical company’s stock, valued at approximately $86,000.

Several other large investors have also recently modified their holdings of the stock. V Square Quantitative Management LLC boosted its holdings in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 248 shares during the period. Spire Wealth Management purchased a new position in Insmed in the 4th quarter worth approximately $47,000. Blue Trust Inc. lifted its position in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Insmed during the third quarter valued at approximately $133,000. Finally, Avior Wealth Management LLC bought a new position in shares of Insmed in the fourth quarter worth approximately $157,000.

Analysts Set New Price Targets

INSM has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday. Guggenheim raised their target price on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Morgan Stanley upped their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. Finally, Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Insider Activity at Insmed

In related news, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 532,207 shares of company stock valued at $41,400,465 in the last 90 days. Corporate insiders own 4.60% of the company’s stock.

Insmed Price Performance

INSM opened at $81.06 on Monday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market cap of $14.50 billion, a price-to-earnings ratio of -14.50 and a beta of 1.11. The stock has a fifty day simple moving average of $74.29 and a two-hundred day simple moving average of $73.61. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million during the quarter, compared to the consensus estimate of $102.31 million. Research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.